Bank of Nova Scotia
CORT icon

Bank of Nova Scotia’s Corcept Therapeutics CORT Stock Holding History

Bank of Nova Scotia’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,778
Closed -$203K – 1035
2025
Q1 		$203K Buy
+1,778
New +$108K ﹤0.01% 936
2022
Q1 		– Sell
-9,728
Closed -$269K – 1209
2021
Q4 		$269K Buy
+9,728
New +$197K ﹤0.01% 1157

Other funds holding CORT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bank of Nova Scotia's CORT Position: Q2 2025 in Review

Bank of Nova Scotia sold out of Corcept Therapeutics (CORT) in Q2 2025, closing a stake of 1,778 shares — an estimated $203K sold.

Bank of Nova Scotia first reported a position in CORT in Q4 2021 and held it in 2 quarters. The position peaked at $269K in Q4 2021. 422 funds tracked by Wall St. Rank hold CORT as of Q2 2025.

  • Bank of Nova Scotia reported no remaining Corcept Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Bank of Nova Scotia sold 1,778 Corcept Therapeutics shares in Q2 2025, an estimated $203K.
  • Bank of Nova Scotia first reported a position in Corcept Therapeutics in Q4 2021 and held it in 2 quarters.
  • Bank of Nova Scotia's Corcept Therapeutics position peaked at $269K in Q4 2021.
  • 422 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2025.

Based on Bank of Nova Scotia's 13F filing for Q2 2025, filed 13 Aug 2025.